Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved..
The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 102(2021) vom: 15. Jan., Seite 389-391 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Çelik, Hülya Gamze [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
20O93L6F9H |
|---|
| Anmerkungen: |
Date Completed 14.01.2021 Date Revised 10.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2020.10.080 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316986445 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316986445 | ||
| 003 | DE-627 | ||
| 005 | 20231225162257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.10.080 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316986445 | ||
| 035 | |a (NLM)33130195 | ||
| 035 | |a (PII)S1201-9712(20)32284-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Çelik, Hülya Gamze |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.01.2021 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cardiac events | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Predictors | |
| 650 | 4 | |a QT prolongation | |
| 650 | 7 | |a Oseltamivir |2 NLM | |
| 650 | 7 | |a 20O93L6F9H |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 700 | 1 | |a Keske, Şiran |e verfasserin |4 aut | |
| 700 | 1 | |a Şener, Ülker |e verfasserin |4 aut | |
| 700 | 1 | |a Tekbaş, Müge |e verfasserin |4 aut | |
| 700 | 1 | |a Kapmaz, Mahir |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, Şükrü Taylan |e verfasserin |4 aut | |
| 700 | 1 | |a Özyıldırım, Aslı |e verfasserin |4 aut | |
| 700 | 1 | |a Aytekin, Saide |e verfasserin |4 aut | |
| 700 | 1 | |a Aytekin, Vedat |e verfasserin |4 aut | |
| 700 | 1 | |a Ergönül, Önder |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 102(2021) vom: 15. Jan., Seite 389-391 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2021 |g day:15 |g month:01 |g pages:389-391 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2020.10.080 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2021 |b 15 |c 01 |h 389-391 | ||